We are a biopharmaceutical company engaged in the research and development of innovative therapeutics to treat cancers and rare diseases. Our mission is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of our patients. These product candidates target biological pathways implicated in a wide range of cancers and certain non-oncology indications. Our discovery and development efforts are guided, when possible, by an understanding of the role of biomarkers, which are indicators of a particular biological condition or process and may predict the clinical benefit of our compounds in defined patient populations. Our clinical-stage pipeline consists of four product candidates, all of which are in targeted patient populations, making ArQule a leader among companies our size in precision medicine. ArQule has a long history of kinase drug discovery and development, having discovered and introduced ten kinase inhibitors into clinical trials. Our drug discovery efforts have been informed by our historical expertise in chemistry, our work in rational drug design and by our insight into kinase binding and regulation. We have applied this knowledge to produce significant chemical matter for a number of kinase targets and to build an extensive library of proprietary compounds with the potential to target multiple kinases in oncology and other therapeutic areas, such as rare diseases. We may bring further preclinical programs forward and interrogate our library against new targets beyond kinases either directly or with collaborators.
Company profile
Ticker
ARQL
Exchange
Website
CEO
Paolo Pucci
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
43221586
ARQL stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
27 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
EFFECT
Notice of effectiveness
21 Jan 20
POSASR
Automatic shelf registration (post-effective amendment)
16 Jan 20
POS AM
Prospectus update (post-effective amendment)
16 Jan 20
POS AM
Prospectus update (post-effective amendment)
16 Jan 20
POS AM
Prospectus update (post-effective amendment)
16 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jan 20
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jan 20
Latest ownership filings
SC 13G/A
Consonance Capital Management LP
17 Feb 21
SC 13G/A
Consonance Capital Management LP
16 Feb 21
SC 13G/A
Arqule Inc
14 Feb 20
SC 13G
Arqule Inc
14 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Beneficial ownership report (amended)
12 Feb 20
SC 13G/A
Arqule Inc
10 Feb 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
4
William G Messenger
16 Jan 20
4
TIMOTHY C BARABE
16 Jan 20
Institutional ownership, Q3 2021
15.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 75.00 k |
Total shares | 19.23 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Pontifax Management 4 G.P. | 8.84 mm | $0.00 |
Integrated Core Strategies | 5.47 mm | $0.00 |
Biotechnology Value Fund L P | 4.90 mm | $0.00 |
Crossmark Global | 14.61 k | $75.00 k |